|
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
PR Newswire (press release) Baxter presented its Phase III data for the HyQ program at the American College of Allergy, Asthma & Immunology. HyQ was shown to be effective in subjects with Primary Immunodeficiency and enabled 94% of subjects to receive full 3 or 4-weekly doses of … Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American … |
View full post on asthma – Google News